Glycyrrhetinic acid ameliorates diosbulbin B‐induced hepatotoxicity in mice by modulating metabolic activation of diosbulbin B

Abstract Exposure to diosbulbin B (DBB), the primary component of the herbal medicine Dioscorea bulbifera L. (DB), can cause liver injury in humans and experimental animals. A previous study found DBB‐induced hepatotoxicity was initiated by CYP3A4‐mediated metabolic activation and subsequent formation of adducts with cellular proteins. The herbal medicine licorice ( Glycyrrhiza glabra L.) is frequently combined with DB used in numerous Chinese medicinal formulas in an effort to protect against DB‐elicited hepatotoxicity. Importantly, glycyrrhetinic acid (GA), the major bioactive ingredient in licorice, inhibits CYP3A4 activity. The study aimed to investigate the protection of GA against DBB‐induced hepatotoxicity and the underlying mechanism. Biochemical and histopathological analysis showed GA alleviated DBB‐induced liver injury in a dose‐dependent manner. In vitro metabolism assay with mouse liver microsomes (MLMs) indicated that GA decreased the generation of metabolic activation‐derived pyrrole‐glutathione (GSH) conjugates from DBB. Toxicokinetic studies demonstrated that GA increased maximal serum concentration (C max ) and area under the serum–time curve (AUC) of DBB in mice. In addition, GA attenuated hepatic GSH depletion caused by DBB. Further mechanistic studies showed that GA reduced the production of DBB‐derived pyrroline‐protein adducts in a dose‐dependent manner. In conclusion, our findings demonstrated that GA exerted protective effect against DBB‐induced hepatotoxicity, mainly correlated with suppressing the metabolic activation of DBB. Therefore, the development of a standardized combination of DBB with GA may protect patients from DBB‐induced hepatotoxicity.